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Abstract Interleukin (IL)-25 (also known as IL-17E) is a
distinct member of the IL-17 cytokine family which induces
IL-4, IL-5, and IL-13 expression and promotes pathogenic T
helper (Th)-2 cell responses in various organs. IL-25 has been
shown to have crucial role between innate and adaptive immu-
nity and also a key component of the protection of gastroin-
testinal helminthes. In this study, to produce bioactive recom-
binant human IL-25 (rhIL-25), the cDNA of mature IL-25 was
performed codon optimization based on methylotropic yeast
Pichia pastoris codon bias and cloned into the expression
vector pPICZαA. The recombinant vector was transformed
into P. pichia strain X-33 and selected by zeocin resistance.
Benchtop fermentation and simple purification strategy were
established to purify the rhIL-25 with about 17 kDa molecular
mass. Functional analysis showed that purified rhIL-25
specifically bond to receptor IL-17BR and induce G-CSF
production in vitro. Further annexin V-FITC/PI staining assay
indicated that rhIL-25 induced apoptosis in two breast cancer
cells, MDA-MB-231 andHBL-100. This study provides a new
strategy for the large-scale production of bioactive IL-25 for
biological and therapeutic applications.
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Introduction
Interleukin-25(IL-25), also known as IL-17E, is the most dis-
tinct member of the IL-17 cytokine family. Originally identified
as homology to IL-17 family members (Fort et al. 2001; Lee
et al. 2001), IL-25 was initially found to accumulate in polar-
ized Th2 cells (Fort et al. 2001). Related studies also demon-
strated that other cell types from hematopoietic or non-
hematopoietic compartments could produce IL-25 under cer-
tain circumstances, such as primary bone marrow-derived mast
cells upon IgE cross-linking (Ikeda et al. 2003), eosinophils and
basophiles upon stem cell factor stimulation (Dolgachev et al.
2009; Wang et al. 2007), lung epithelial cells upon allergic
response (Angkasekwinai et al. 2007), and alveolar macro-
phages after particle inhalation (Kang et al. 2005). The accu-
mulation of IL-25 could also be seen in intestinal epithelial cells
and brain capillary endothelial cells (Sonobe et al. 2009; Zaph
et al. 2008). Many investigations confirmed the ability of
different cell types to produce IL-25, while the mechanisms
to control IL-25 production remain unclear.
IL-25 share the same receptor with IL-17B, named IL-
17RB, IL-17BR, or Evi27, which was also identified based
on sequence similarity to the IL-17 receptor. However, IL-25
has higher binding affinity to IL-17RB compared to that of IL-
17B (Lee et al. 2001; Shi et al. 2000; Tian et al. 2000). Further
study showed that IL-17RA and IL-17RB are both required for
activating signals in response to IL-25, although IL-25 did not
bind to IL-17RA (Rickel et al. 2008). Currently, the down-
stream targets of IL-25 signaling pathway still remain unclear.
As a distinct cytokine of the IL-17 family, IL-25 has the
least structural homology with the prototypical IL-17 family
member, IL-17A, which indicated why its biologic activities
are distinct from other IL-17 familymembers. The cytokines of
IL-17 family, not IL-25, induce the production of proinflam-
matory cytokines and play similar roles in the development of
certain diseases. Alternatively, IL-25 has its unique abilities in
regulating Th2 cell-type immune responses. It also plays a
decisive role both in the induction of a protective response
against parasites and in the initiation of innate and adaptive
pro-allergic responses (Monteleone et al. 2010). It is interesting
that IL-25was also involved in anti-tumor (Benatar et al. 2008,
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2010) and anti-inflammatory activities based on various studies
of human and animal models (Mchenga et al. 2008).
Until now, the recombinant human IL-25 (rhIL-25) is tran-
siently produced using recombinant adenovirus or expressed
in cell lines including human embryonic kidney (HEK) 293
cells or Sf9 insect cells on a small scale (Fort et al. 2001; Hurst
et al. 2002). Commercial rhIL-25 is generated from an
Escherichia coli expression systemwhich may involve proper
fold problem. In this study, using a eukaryotic expression
system of P. pastoris , we established a more efficient and
cost-effective method to produce functional rhIL-25 in large
quantities. This will facilitate further study of its mechanisms
in the pathogenesis of immune diseases, the structure–func-
tion relationship, and possible clinical applications.
Materials and methods
Strains and reagents
P. pastoris strain X-33, expression vector pPICZαA, and
antibiotic zeocin were products from Invitrogen (USA).
Mouse anti-human IL-25 monoclonal antibody and E. coli-
derived rhIL-25were purchased fromR&D (USA). Restriction
enzymes were products of New England Biolabs (USA).
Primers were synthesized by Sangon Biological Co., Ltd.
(Shanghai, China). Other reagents were obtained from stan-
dard commercial sources and were of reagent grade.
Synthesis of human IL-25 gene and construction
of expression vector
To improve the production of recombinant hIL-25 in P.
pastoris , we carried out a codon optimization of the hIL-25
gene and constructed an artificial gene according to the spe-
cific codon usage of P. pastoris (codon usage database from
http://www.kazusa.or.jp/codon). We designed a cloning
approach based on synthetic overlapping primers and a PCR
assembly strategy to construct a synthetic hIL-25 cDNA
fragment without the signal peptide sequence (Xiong et al.
2004). The hIL-25 cDNA (GenBank accession number
BC069565) was used as template for optimization to generate
a set of ten overlapping oligonucleotides (as showed in
Table 1), of which G+C content was adjusted to meet codon
preference. A mixture of the oligonucleotides (10 ng each)
was used in a first-round ten cycles of PCR procedure using
pfu polymerase to generate most sections of the coding se-
quence. Then, the region for Xho I restriction site and Kex2
and Ste13 cleavage sites of α-factor signal sequence of P.
pastoris were added to the 5′ terminal of the synthesized
fragment in the second-round PCR using the most 5′ end
primer N1 (see Table 1). At the same time, NotI restriction
site was linked to the 3′-terminal using the most 3′ end primer
C1. The complete artificial DNA was first cloned into the
Xho I–Not I frame of vector pBluescript SK and confirmed
by automated DNA sequencing. Then, the certified fragment
was directly cloned into pPICZαA, in-frame with the α-factor
signal sequence under the control of the AOX1 promoter. The
C-terminal stop codon to terminate translation is immediate
after the last amino acid of hIL-25.
Transformation of P. pastoris and screening
Yeast transformation was performed on an electroporation
system (Bio-Rad, USA) according to the manufacturer's in-
struction. The recombinant vector pPICZαA-hIL-25 was
linearized with Sac I and electroporated into competent P.
pastoris strain X-33. The electroporated mixture was spread
on YPDS plates (1 % yeast extract, 2 % peptone, 2 % glucose,
1 mol/l sorbitol, 2 % agar) containing 100 μg/ml, 500 μg/ml,
1 mg/ml, or 2 mg/ml zeocin, respectively, for growth selec-
tion. After 72 h of incubation at 30 °C, the positive colonies
were certified for integration of hIL-25 gene into the Pichia
genome by PCR using the primers of 5′ AOX , 3′ AOX , and IL-
25 gene-specific primers. The confirmed transformants were
kept for further analysis.
Shake flask expression screening of rhIL-25 expression stain
The positive transformants were tested for their ability to
secret rhIL-25 into the culture medium. Five milliliters of
MGYH medium (1.34 % YNB, 1 % glycerol, 4×10−5 %
biotin, 0.004 % histidine) of shake flask cultures from the P.
pastoris clones (hIL-25 /X-33 clones) was grown overnight at
30 °C in 25-ml baffled flasks (250 rpm) to an OD600 between
2 and 6. The cultures were centrifuged for 5 min at 3,000g.
The pellets were then transferred to 20 ml of MMH (1.34 %
YNB, 4×10−5 % biotin, 0.5 % methanol, 0.004 % histidine)
medium to culture at OD600 of 1.0 in 100-ml baffled flasks to
induce expression at 30 °C. In each of the following 4 days,
puremethanol was added to the culture to a final concentration
of 1 % (v /v ), while 200 μl of cell culture was collected and
centrifuged at 12,000g for 5 min at 4 °C. Supernatants were
collected to monitor the expression and secretion of rhIL-25
by SDS-PAGE separation, followed by Coomassie blue stain.
Bench-scale fermentation and purification procedure
Fermentations were performed in a 5-l working volume biore-
actor (Bioflo 3000, NewBrunswick Scientific, USA) according
to Invitrogen instructions for P. pastoris fermentation. Two
liters of basal salts medium (4.25 ml/l orthophosphoric acid,
9.4 mM MgSO4, 1 mM CaSO2, 16.4 mM K2SO4, 11.4 mM
KOH, and 50 ml/l glycerol) was sterilized in the bioreactor.
Ammonium was used as both a pH control reagent and a
nitrogen source. PTM1 trace salts (2 ml/l; 24 mM CuSO4,
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0.53 mM NaI, 19.87 mM MnSO4, and 0.83 mM Na2MoO4,
0.32 mM boric acid, 2.1 mM CoCl2, 0.15 mM ZnCl2, 0.23 M
FeSO4, and 0.82 mM biotin) were added after sterilization. The
certified rhIL-25 producing P. pastoris strain was grown as
seed broth in 200ml of BMGY (2% peptone, 1% yeast extract,
100 mm potassium phosphate, pH 6.0, 1.34 % yeast nitrogen
base (without amino acid), 0.4 μg/ml biotin, 1 % glycerol)
overnight till OD260 reached 4 and then inoculated into 2.0 L
basal salts medium in a fermentor.
Throughout the fermentation process, temperature,
dissolved oxygen (DO) concentration, and pH were monitored
and maintained at set points of 30 °C, 30 % and 5.0, respec-
tively. DO concentration was maintained above 30 % by
enriching the inlet air with pure oxygen passing through a
mass flow controller when needed. A glycerol-fed-batch phase
was carried out in which biomass was bulked up to the desired
cell density using 50% glycerol feed containing 12 ml/l PTM1
trace salt. The exhaustion of glycerol was indicated by a spike
in the DO, which happened 24–26 h after inoculation to the
OD value at 600 nm reached around 100–120. After the
growth phase on glycerol was finished, induction was carried
out by feeding methanol (containing 12 ml/l PTM1) at a
gradient feed rate into the fermentor.
The induction phase was maintained for 44 h, and then the
culture medium was centrifuged at 8,000g for 30 min at 4 °C.
The supernatant was clarified by a bacterial filter (0.45 μm)
and concentrated by ultrafiltration using a Pellicon cassette
(Millipore, USA) with a molecular cutoff of 1,000 Da. The
retention liquid was then run a buffer exchange against 50 mM
Tris-Cl, 1 mM EDTA (pH 8.8), and loaded onto Q sepharose
Fast Flow anion-exchange resin (GE healthcare, USA) equil-
ibrated by the same buffer. The flow-through, which contained
rhIL-25, was collected and further depurated through a gel
filtration chromatography medium Sephacryl S-100 High
Resolution (GE healthcare, USA) balanced with 20 mM PB
(pH7.4). Fractions of purified rhIL-25 were lyophilized after
the addition of trehalose to a final concentration of 15 %.
SDS-PAGE and western blot analysis
Protein samples were separated on 15 % SDS-PAGE gels and
stained with sliver or Coomassie Blue R-250. To characterize
the recombinant hIL-25, samples were also electroblotted onto
PVDF membrane (Millipore,USA) using Mini Trans-Blot®
Cell (Bio-Rad, USA) according to the manufacturer's instruc-
tions. The membrane was blocked with 5 % milk in TBST
(10M Tris–HCl, 150 mMNaCl, pH 8.0, and 0.1 % Tween 20)
for 2 h at room temperature. The membrane was then incu-
bated for 2 h at room temperature with mouse anti-hIL-25
monoclonal antibody (R&D,USA). After washing four times
with TBST, the membrane was incubated for 1 h with
peroxidase-conjugated goat anti-mouse IgG (R&D, USA).
The membrane was washed three times with TBST, and the
blot was visualized by chemiluminescence via the Pierce
SuperSignal ECL detection kit (Pierce, Thermo Fisher,
USA). N-terminal sequencing of rhIL-25 was performed by
Shanghai Applied Protein Technology Co. Ltd.
IL-25 interaction assay
The binding ability of recombinant rhIL-25 to its conjugate
IL-17RB (also IL-17BR) was tested by pull-down assay.
Purified rhIL-25 was incubated with IL-17BR-Fc chimera
(R&D, USA) in fresh phosphate-buffered saline (PBS,
pH 7.4) for 1 h at room temperature. The IL-17BR-Fc was
pulled down by its Fc-tag using rProteinA Resin (GE
Healthcare, USA). The beads were washed with PBS three
times and then eluted with 0.1 M glycine-HCl (pH3.0). A
donkey anti-goat IgG (Santa Cruz, USA) was also used in-
stead of IL-17BR-Fc as a negative control.
Table 1 Primers used for the synthesis of optimized hIL-25 gene













a Sequences added to introduce restriction endonuclease recognition sites (XhoI and NotI) are italicized
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In vitro biological activity assay
Biological activity was determined by adding rhIL-25 prepara-
tions to HEK293 cells or human lung fibroblast cell line HFL-I
cells (Cat. GNHu43 and GNHu 5, respectively; Shanghai Cell
Collection, SIBS, Shanghai, China) to assay G-CSF mRNA
and protein expression level changes. The HEK293 cells were
cultured at 2×105 cells per well in six-well plates (Corning,
USA) in 2 ml DMEMmedium (Gibco, USA) containing 10 %
new-born calf serum (NCS) at 37 °C, 5%CO2, while the HFL-
I cells were cultured at 1×105 cells per well in MEMαmedium
containing 10 % heat-inactivated fetal bovine serum (FBS).
Then, the cells were starved of serum for 24 h. Purified rhIL-25
was diluted and added into a six-well plate (2 ml/well) in
triplicate to reach concentrations of 50, 100, 200, and 400 ng/
ml. After 24 h of incubation, the cells were lysed for RNA
extraction using TRIzol reagent and operated according to
manufacturer's instruction (Invitrogen). First-strand cDNA syn-
thesis was performed using RevertAid First Strand cDNA
synthesis kit (Invitrogen). The product of first-strand cDNA
synthesis was used directly for real-time PCR assay. The
primers used for G-CSF amplification were 5′-CAGTTAC
AATGTGACAGTGGAGGG-3′ and 5′-TTTGACTCC
CGAACATCACCGAC-3′, respectively. Commercially avail-
able recombinant hIL-25 derived from E. coli (R&D, USA)
was also used as control. The mRNA level of GAPDH was
used as normalization control.
G-CSF production in cell culture supernatant was also
assayed using a human G-CSF quantikine ELISA kit
(R&D). The cell culture and rhIL-25 treatment is the same
as that for real-time PCR. After 24 h treatment with rhIL-25,
the culture supernatant was collected for ELISA assay
according the manufacturer's manual.
Hoechst staining and flow cytometric assay of apoptosis
Two breast cancer cell lines, HBL-100 (Cat. GNHu10,
Shanghai Cell Collection, SIBS) and MDA-MB-231 (No.
HTB-26, ATCC, USA), were seeded at a density of 1×105
cells per well in 0.5 ml DMEMmedium containing 10%NCS
in a 24-well plate (Corning, USA) and cultured to 80 %
saturation at 37 °C, 5 % CO2. After 12 h of serum starvation,
cells were treated with rhIL-25 for 4 or 24 h at 37 °C, 5%CO2.
At indicated time, cells were washed twice with PBS, then
Hoechst 33342 solution (Invitrogen) was added at 1 μg/ml,
and incubated for 30 min at room temperature. Images were
taken with a fluorescene microscope (IX71, Olympus, Japan).
Apoptotic cells were measured by annexin V-FITC/
propidium iodide (PI) staining and flow cytometry. Briefly,
HBL-100 andMDA-MB-231 cells were seeded at a density of
4×105 cells per well in a six-well plate and cultured to 80 %
saturation at 37 °C, 5 % CO2. After 12 h of serum starvation,
cells were treated with gradient concentration of rhIL-25 for
8 h at 37 °C, 5 % CO2. After that, cells were harvested using
citric acid, washed twice with cold PBS, and then resuspened
in 500 μl binding buffer. Afterward, 5 μl annexin V-FITC and
5 μl PI (BD, USA) were added and incubated with cells for
15min in the dark at room temperature and then analyzed on a
flow cytometer (Epics Altra system, Beckmen-Coulter, USA;
analysis software is EXPO32 V1.2 Analysis). Early apoptotic
(lower right quadrant) and late apoptotic (upper right quad-
rant) cells were identified and expressed as percentage of cells.
GenBank accession numbers
The accession number of wild-type IL-25 is BC069565; the
accession number of codon-optimized IL-25 is KF360054.
Results
Construction of the recombinant expression vector
The full-length of hIL-25 cDNA was 534 bp, encoding a
polypeptide of 177 amino acid residues with a putative signal
sequence and pre-peptide of 32 amino acid residues. The 438-
bp fragment coding for mature IL-25 proceeded for codon
optimization based on P. pastoris preference for efficiency of
rhIL-25 production. The sequence alignment result showed
that the codon-optimized IL-25 shares 72 % identity with the
wild-type IL-25 after averaging the distribution of G+C con-
tent and eliminating the potential hairpin structure. The sub-
stitute of nucleotides does not alter their coding amino acid
sequences. DNA sequencing of the recombinant vector con-
firmed the accuracy of the reading frame of IL-25 . The syn-
thesized DNA was directly inserted into the open reading
frame of α-factor signal sequence of the P. pastoris expres-
sion vector pPICZαA under the regulation ofAOX1 promoter.
Transformation and screening of transformants at shaking
flask level
The resulting vector, pPICZαA-rhIL-25 , was transformed
into P. pastoris by electroporation and plated on YPDS me-
dium containing increasing concentrations of zeocin for the
rapid screening of multi-copy transformants. The number of
transformants decreased with the increase of antibiotic con-
centration after 3 days of incubation. Colony PCR screening
of the positive recombinant was performed to confirm the
integration of recombinant vector into the Pichia genome.
Then, positive colonies were cultured and induced to ex-
press the recombinant proteins according to the manufacturer's
instruction. Transformants fromYPDS plates in the presence of
different concentrations of zeocin were selected for expression
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Fig. 1 Analysis of total proteins
in culture medium of P. pastoris
expressing rhIL-25. Supernatants
were collected at the indicated
time after induction by methanol.
The samples were separated on
15 % SDS-PAGE and stained
with silver (a) or Coomassie
brilliant blue (c , d). a Shake flask
culture medium of P. pastoris
strain X-33 transformed by wild
hIL25 . b Western blot analysis.
c , d Fermentation culture
supernatants of X-33 transformed
by codon-optimized hIL25 .
c Non-reduction, loading buffer
without β-mercaptoethanol.
d Reduction, loading buffer
with β-mercaptoethanol
Fig. 2 Purification of rhIL-25 protein. a The fermentation supernatant
was concentrated by ultrafiltration and then the buffer exchanged against
50 mM Tris–HCl and 1 mM EDTA, loaded onto Q sepharose Fast Flow
resin, and eluted using NaCl gradient from 0 to 1 M. The rhIL-25 protein
was flowing through the Q Sepharose FF, while the containments were
bound by the column. b The fractions were separated on 15 % SDS-
PAGE. Lane M molecular weight marker. Lane 1 fermentation superna-
tant at 44 h after methanol induction. Lane 2 after buffer exchange. Lane
3 flow-through of Q FF. Lane 4 wash-off using balance buffer. Lane 5–9
eluate from Q Sepharose FF
Fig. 3 IL-17BR binding assay. Purified rhIL-25 was evaluated by its
capacity to interact with IL-17BR. Recombinant hIL-25 was incubated
with IL-17BR-Fc chimera and then pulled down with rProtein A resin
which specifically binds the Fc-tag on IL-17BR-Fc chimera. Donkey
anti-goat IgG was used as a negative control for non-specific binding.
Bound proteins were analyzed by SDS-PAGE and Coomassie staining.
Lanes represent flow-through (1), wash (2), and elution fractions (3)
from the resin using a rhIL-25 only, b rhIL-25 incubated with IL-17BR-
Fc chimera, and c rhIL-25 incubated with donkey anti-goat IgG
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screening. SDS-PAGE and western blot analysis showed that
rhIL-25 was successfully expressed in the culture medium of P.
pastoris X-33 transformants. Secreted rhIL-25 from wild-type
hIL-25 transformants could be detected in silver-stained gel,
while it could be clearly identified with Coomassie blue stain-
ing in codon-optimized transformants (shown in Fig. 1). The
product demonstrated as a 17- and a 34-kDa band; both bands
were identified by western blot using a mouse anti-hIL-25
monoclonal antibody. The 34-kDa band was considered to be
a homodimer form of the 17-kDa hIL-25. SDS-PAGE also
showed a progressive accumulation of the rhIL-25, starting at
24 h post-induction, and reached the peak at 96 h. Prolonged
Fig. 4 IL-25 induces G-CSF
production. a , b IL-25 stimulates
G-CSF mRNA expression in
HFL-1 and HEK293 cells. The
cells were treated with IL-25 and
the mRNA expression level of
G-CSF was examined by real-
time RT-PCR. GAPDH mRNA
levels were used as normalization
controls. The data are presented as
the fold increase after IL-25
induction compared with medium
only (no IL-25 treatment) cell. c
IL-25 induces the production of
G-CSF protein, HFL-1 cells were
treated with IL-25 in increased
concentration for 24 h, and
G-CSF levels in the culture
medium were measured by
ELISA
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induction could not increase the amount of total rhIL-25 in the
culture supernatant.
Large-scale expression and purification of rhIL-25
One of the transformants with highest expression was grown
on a 5-l bioreactor and induced with methanol for 48 h.
Culture medium was collected and centrifuged to generate
supernatant every 4 h. The recombinant protein expression
started 16 h after methanol induction and reached the peak at
44 h (shown in Fig. 1). At the end of fermentation, the wet
weight of yeast reached 260 g per liter of broth volume, while
the volume of supernatant increased to 2.6 L. The rhIL-25 in
culture supernatant was estimated to be 100 mg/l based on
SDS-PAGE results. The culture supernatant was collected and
concentrated using membrane ultrafiltration. Subsequently,
rhIL-25 was allowed to pass through the Q sepharose Fast
Flow column, while most of the contaminants were absorbed
(Shown in Fig. 2). The rhIL-25 was further polished through
high-resolution gel filtration to remove trace impurities.
Finally, we got 39.6 mg purified rhIL-25 per liter of culture
supernatant in monomer form.
N-terminal sequencing result indicated that the five amino
acid residues at the N-terminal of the rhIL-25 were YSHWP,
which matched with that of the deduced mature IL-25.
Functional characterization and bioactivity assay of rhIL-25
The functionality of rhIL-25 was evaluated by testing its
capacity to bind IL-17BR using a pull-down assay. As shown
in Fig. 3, we detected the specific interaction of the purified
recombinant rhIL-25 with IL-17BR-Fc chimera. The
rProteinA affinity gel was also used alone in this assay for it
non-specifically binds to rhIL-25. The biological activity of
rhIL-25 was detected by its ability to directly stimulate G-CSF
production from two cell lines in vitro. As shown in Fig. 4,
rhIL-25 stimulated G-CSF mRNA expression in both
HEK293 and HFL-1 cells, with higher expression in HFL-1
cell. G-CSF protein production from HFL-1 cells was con-
firmed by ELISA. The activity of the purified rhIL-25 was
comparable with the commercially available recombinant
hIL-25.
Recombinant hIL-25 induces apoptosis in breast cancer cells
by annexin V-FITC/PI staining assay
To investigate whether apoptosis occurs in rhIL-25-treated
breast cancer cells, we performed a Hoechst33342 staining
assay to detect apoptosis-induced chromosome fragmentation.
Hoechst33342 staining was used to visualize the nuclear
morphology following rhIL-25 treatment (shown in Fig. 5).
Fluorescent signals were detected in nucleic regions of cells
after 4 h of treatment with 50 ng/ml rhIL-25, and more
obviously, morphologic changes of apoptosis such as con-
densed chromatin and shrunken nucleus were detected after
24 h of treatment.
To confirm the various stages of apoptosis or necrosis,
MDA-MB-231 and HBL-100 cells were treated with the indi-
cated concentrations of rhIL-25 for 8 h, followed with annexin
V-FITC/PI staining and FACS analysis. Figure 6 shows a dot–
plot display produced from annexin V-FITC/PI with flow
cytometry. After the administration of rhIL-25 for 8 h, apopto-
sis was induced in both cells in a dose-dependent manner.
Discussion
The aim of the current work was to produce a large amount of
soluble and bioactive rhIL-25 suitable for biological studies
with less cost and no denaturing agents or refolding steps
Fig. 5 Fluorescence
photomicrographs of two breast
cancer cells with Hoechst 33242
staining after rhIL-25 treatment.
a–c HBL-100 cells. d–f , MDA-
MB-231 cells. a , d Untreated
with rhIL-25. b , e , At 4 h after
treatment with 50 ng/ml rhIL-25.
c , f At 24 h after treatment with
50 ng/ml rhIL-25. ×400
magnification
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present in the E. coli expression system. Human IL-25 has been
produced transiently in human 293 cells using recombinant
adenovirus or Sf9 insect cells (Fort et al. 2001; Hurst et al.
2002), while the productivity of the recombinant protein was
Fig. 6 Cell apoptosis was
induced with rhIL-25. After 8 h
of treatment of rhIL-25 with
indicated dosages, HBL-100
and MDA-MB-231 cells were
harvested and stained with
annexin V-fluorescein and PI.
Percentage of annexin-V/PI
stained cells was determined
by flow cytometry
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unknown. It was also produced as inclusion bodies in E. coli ,
which need denaturing and refolding steps (unpublished data in
this laboratory).
Yeasts, particularly the methylotrophic yeast P. pastoris ,
have numerous advantages as a host system for the production
of recombinant heterologous proteins. They are much easier to
perform and cheaper in cost compared with that of bacterial
expression systems. At the same time, P. pastoris , as a eukary-
ote, thereby provides the potential for producing soluble re-
combinant proteins with correct folding and post-translational
modifications (Cregg et al. 2009; Damasceno et al. 2012).
To obtain the high-quality and extracellular expression of
rhIL-25, we chose pPICZαA as the expression vector and P.
pastoris X-33 as the host strain. Many proteins produced in P.
pastoris are similar to those produced in mammalian cells
based on synthesis, structure, and bioactivity. The expression
vector pPICZαA has an α-factor secretion signal sequence,
which has been used with great success. However, although
the rhIL-25 was presently secreted in P. pastoris , the low
secretion level using a wild-type gene restricted its yield, as
shown in Fig. 1a, b; rhIL-25 can hardly be discriminated using
silver staining. There are many factors that markedly influence
the expression of foreign genes, including P. pastoris codon
bias, base content of foreign genes, transcriptional and trans-
lational blocks, and secondary structure of mRNA (Cregg
et al. 2009; Woo et al. 2002). To increase the secretion ex-
pression level, we optimized the gene of interest by means of
substituting rare codons with P. pichia preferable triplets. At
the same time, we balanced the G+C content, removed the A/
T or G/C repeats, and avoided the formation of hairpin or
special secondary structure of hIL-25 mRNA(Li et al. 2008).
The productivity of rhIL-25 was much higher using codon
optimized rhIL-25 .
The function of rhIL-25 was verified by its binding capa-
bility with IL-17RB. The biological activity of rhIL-25 was
confirmed by its ability to induce G-CSF production in pul-
monary fibroblasts HFL-1 and renal epithelium cell HEK293,
which is consistent with published results (Pan et al. 2001).
We also tried some breast cancer cell lines to detect whether
they can produce G-CSF after rhIL-25 treatment. We found
that more dominantly rhIL-25 can induce the death rate of
breast cell. Apoptosis-induced chromosome fragmentation
was detected using Hoechst33342 staining. Annexin V-
FITC/PI staining assay indicated that rhIL-25 induced apo-
ptosis in breast cancer cell MDA-MB-231 and HBL-100,
which was in agreement with Furuta's report that IL-25 causes
apoptosis of some breast cancer cells (Furuta et al. 2011).
As observed by non-reduced and reduced SDS-PAGE, The
rhIL-25 produced by P. pastoris was mainly homodimers,
which is in agreement with the finding that IL-17s adopt a
cystine knot fold (Hymowitz et al. 2001). IL-17A had also been
expressed in P. pastoris as both monomer and homodimer
forms (Murphy et al. 1998). IL-25 has 11 cysteines in total,
more than that of IL-17A and other members in IL-17 family,
which indicate its unique character. The exact disulfide bonds
within polypeptide or between peptide chains need further
study. In this study, although the homodimer form of rhIL-25
was shown in culture medium, the monomer form was the
unique form after purification. The method of purification also
indicated rhIL-25 having a distinctive structure. The bond in
the homodimer is probably a weak disulfide bonds. To learn the
distinct biological activity of this cytokine, further work is
needed to assess the manner of dimerizing and the importance
of inter-peptide disulfide bonds forming.
In conclusion, we have described a highly efficient way of
producing large quantities of functional rhIL-25 using a P.
pastoris expression system. This system may facilitate further
studies of its structure–function relationship in the near future.
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